Contributors |
|
ix | |
Preface |
|
xi | |
|
Chapter 1 Artificial kidney: A chemical engineering challenge |
|
|
1 | (20) |
|
|
|
1 | (3) |
|
|
4 | (2) |
|
3 Transport properties of membranes for artificial kidney |
|
|
6 | (2) |
|
4 Compartmental modeling for artificial kidney |
|
|
8 | (3) |
|
5 Membrane modules for renal replacement therapy |
|
|
11 | (1) |
|
6 Water quality management in artificial kidney |
|
|
12 | (1) |
|
7 The future of renal replacement therapy: Bioartificial kidney and implantable artificial kidney |
|
|
13 | (2) |
|
8 Conclusions and future trends |
|
|
15 | (6) |
|
|
18 | (3) |
|
Chapter 2 Membrane application for liver support devices |
|
|
21 | (24) |
|
|
|
|
|
21 | (1) |
|
|
22 | (1) |
|
3 Development of blood purification systems |
|
|
23 | (3) |
|
|
26 | (8) |
|
|
26 | (1) |
|
|
26 | (1) |
|
4.3 Reactors with immobilized enzymes |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
27 | (1) |
|
4.6 Plasma exchange and continuous hemodiafiltration |
|
|
28 | (1) |
|
4.7 Molecular therapy of the absorbent recirculation system |
|
|
28 | (4) |
|
|
32 | (2) |
|
|
34 | (3) |
|
|
35 | (1) |
|
5.2 Types of hepatocyte culture systems |
|
|
36 | (1) |
|
|
36 | (1) |
|
|
37 | (5) |
|
6.1 Implantable engineered tissue for humanized mouse models |
|
|
38 | (2) |
|
6.2 Implantable therapeutic engineered liver tissue |
|
|
40 | (1) |
|
6.3 Design criteria for implantable systems |
|
|
40 | (1) |
|
6.4 Natural scaffold chemistry and modifications |
|
|
40 | (2) |
|
7 Conclusion and future trends |
|
|
42 | (3) |
|
|
42 | (3) |
|
Chapter 3 Membrane bioreactors for (bio-)artificial lung |
|
|
45 | (32) |
|
|
|
|
|
|
|
45 | (1) |
|
2 Milestones in ECMO development to date |
|
|
46 | (4) |
|
3 Limitations of ECMO/ECLS |
|
|
50 | (2) |
|
4 Computational fluid dynamics for the optimization of the oxygenator design |
|
|
52 | (1) |
|
5 Surface treatments for improving the hemocompatibility of blood contacting surfaces in ECMO circuits |
|
|
53 | (4) |
|
6 Biohybrid/bioartificial approaches |
|
|
57 | (4) |
|
7 Wearable or implantable artificial lung |
|
|
61 | (2) |
|
8 The implantable artificial lung |
|
|
63 | (1) |
|
9 The development of microfluidic artificial lungs |
|
|
64 | (2) |
|
10 Tissue engineered lungs |
|
|
66 | (1) |
|
11 Conclusions and future trends |
|
|
67 | (10) |
|
|
68 | (9) |
|
Chapter 4 Membrane bioreactors for bio-artificial pancreas |
|
|
77 | (32) |
|
|
|
|
|
1 Introduction: The pancreas |
|
|
77 | (4) |
|
1.1 Anatomy and physiology |
|
|
77 | (1) |
|
1.2 Mechanisms of glycemic regulation |
|
|
78 | (1) |
|
1.3 Physiopathology and treatment |
|
|
79 | (2) |
|
2 The concept of bioartificial pancreas |
|
|
81 | (2) |
|
3 Overview of the specificities of currently developed BAP |
|
|
83 | (11) |
|
3.1 Number and potential sources of pancreatic islets |
|
|
84 | (3) |
|
3.2 Mass transfer issues in BAP and implantation site |
|
|
87 | (7) |
|
4 Porous scaffolds---Membranes |
|
|
94 | (1) |
|
5 Conclusions and future trends |
|
|
95 | (14) |
|
|
100 | (9) |
|
Chapter 5 Membrane devices for blood separation and purification |
|
|
109 | (18) |
|
|
|
|
|
109 | (2) |
|
2 Requirements for an effective apheresis |
|
|
111 | (2) |
|
3 Main differences between centrifugation and filtration systems |
|
|
113 | (3) |
|
|
114 | (1) |
|
|
114 | (1) |
|
3.3 Mixed systems: Membranes and centrifuges |
|
|
115 | (1) |
|
4 Discontinuous and continuous flow systems |
|
|
116 | (1) |
|
|
116 | (6) |
|
|
116 | (2) |
|
5.2 Semiselective plasmas (plasma separation through secondary membranes, or double filtration or cascade filtration) |
|
|
118 | (1) |
|
5.3 Selective plasma tracking (selective absorption) |
|
|
118 | (2) |
|
5.4 Apheresis of lipidic proteins |
|
|
120 | (1) |
|
|
120 | (1) |
|
5.6 Therapeutic cytoapheresis |
|
|
120 | (2) |
|
6 Donations of autologous or allogeneic blood components |
|
|
122 | (1) |
|
7 Conclusion and future trends |
|
|
123 | (4) |
|
|
125 | (2) |
|
Chapter 6 Numerical prediction of blood damage in membrane-based biomedical assist devices |
|
|
127 | (30) |
|
|
|
|
127 | (2) |
|
2 Properties of red blood cells |
|
|
129 | (6) |
|
2.1 Red blood cell structure |
|
|
129 | (3) |
|
2.2 Mechanical properties |
|
|
132 | (3) |
|
3 Phenomenology of hemolysis and blood damage |
|
|
135 | (2) |
|
4 Quantification of blood damage |
|
|
137 | (1) |
|
5 Experimental data on blood damage |
|
|
138 | (3) |
|
6 Current modeling approaches for blood damage prediction |
|
|
141 | (10) |
|
|
142 | (1) |
|
6.2 Limitations of empirical stress-based models |
|
|
143 | (4) |
|
|
147 | (4) |
|
7 Conclusions and future trends |
|
|
151 | (6) |
|
|
153 | (3) |
|
|
156 | (1) |
|
Chapter 7 Membrane scaffolds for 3D cell culture |
|
|
157 | (34) |
|
|
|
|
|
1 Membrane scaffolds for tissue engineering applications |
|
|
157 | (4) |
|
1.1 Tissue engineering principles |
|
|
157 | (1) |
|
1.2 Application of tissue engineering methods for 3D cell culture |
|
|
157 | (1) |
|
1.3 Prerequisites of membranes for 3D cell culture |
|
|
158 | (1) |
|
1.4 Biomaterials for membranes fabrication |
|
|
159 | (2) |
|
2 Methods of membranes fabrication |
|
|
161 | (11) |
|
2.1 Conventional techniques |
|
|
161 | (4) |
|
2.2 Biofabrication methods for membranes in tissue engineering |
|
|
165 | (7) |
|
3 Use of membranes for cell culture in tissue engineering |
|
|
172 | (9) |
|
3.1 Limits of conventional tissue engineering |
|
|
173 | (1) |
|
3.2 Layer-by-layer bioassembly of cellularized membranes for tissue engineering |
|
|
174 | (7) |
|
4 Conclusions and future trends |
|
|
181 | (10) |
|
|
184 | (7) |
|
Chapter 8 Artificial oxygen carriers |
|
|
191 | (24) |
|
|
|
191 | (3) |
|
1.1 Oxygen is both: A blessing and a curse |
|
|
191 | (3) |
|
2 The role of AOCs in the context of artificial organs and tissue engineering |
|
|
194 | (4) |
|
2.1 Why has evolution developed such strategies? |
|
|
195 | (3) |
|
|
198 | (10) |
|
3.1 Hemoglobin-based AOCs |
|
|
198 | (5) |
|
3.2 Perfluorocarbon-based AOCs |
|
|
203 | (5) |
|
4 Conclusions and future trends |
|
|
208 | (7) |
|
|
209 | (1) |
|
|
209 | (6) |
|
Chapter 9 Membrane bioreactors for digestive system to study drugs absorption and bioavailability |
|
|
215 | (22) |
|
|
|
|
|
215 | (3) |
|
2 Anatomy of the GI tract |
|
|
218 | (3) |
|
3 Physiology of the GI tract |
|
|
221 | (2) |
|
|
221 | (1) |
|
|
222 | (1) |
|
|
222 | (1) |
|
|
222 | (1) |
|
4 Modeling of drugs' absorption and bioavailability |
|
|
223 | (7) |
|
4.1 Single and two-compartment models |
|
|
223 | (1) |
|
4.2 Five-compartments model |
|
|
224 | (6) |
|
|
230 | (4) |
|
6 Conclusion and future trends |
|
|
234 | (3) |
|
|
236 | (1) |
Index |
|
237 | |